key: cord-0906281-drls9rr5 authors: Wilson, Nick; Mansoor, Osman D; Boyd, Matthew J; Kvalsvig, Amanda; Baker, Michael G title: We should not dismiss the possibility of eradicating COVID-19: comparisons with smallpox and polio date: 2021-08-09 journal: BMJ Glob Health DOI: 10.1136/bmjgh-2021-006810 sha: 9d8ce742b024b000e757efbc89e488fdf29092f2 doc_id: 906281 cord_uid: drls9rr5 nan Elimination and eradication of disease are among the ultimate goals of public health 1 (for definitions see box 1). Vaccination has globally eradicated smallpox, rinderpest (a cattle disease that caused famines 2 ) and two of the three serotypes of poliovirus. 3 Three other vaccine-preventable diseases are eradicable globally with current technology, 4 with measles the leading contender and with MMR vaccination potentially eradicating mumps and rubella at the same time. Some other diseases are close to being eradicated but without use of vaccines such as with the Guinea Worm Eradication Programme. 5 Similarly, China has recently eliminated malaria with a range of non-vaccination tools, to become the 40th country to be certified malaria-free. 6 Is COVID-19 also potentially eradicable? Or is it inevitably endemic having established itself across the world? Commentators have focused on the challenges of reaching population (herd) immunity, 7 yet population immunity is not essential and was not achieved for smallpox, which was eradicated through ring vaccination. As proof of concept for COVID-19 eradication, several countries and jurisdictions have achieved elimination without vaccination, using new and established public health and social measures (PHSMs) (eg, border control, physical distancing, mask wearing, testing and contact tracing supported by genome sequencing). 8 Successful jurisdictions have included those with vast land borders such as China, high population densities such as Hong Kong, 9 but also island nations such as Iceland and New Zealand, although with occasional outbreaks from border control failures that have been brought under control. 10 Summary box ► With the success of public health and social measures (PHSMs) at eliminating COVID-19 in several jurisdictions, combined with the arrival of safe and highly effective vaccines, the question is raised: is global eradication of COVID-19 feasible? ► Our scoring for eradicability suggests that COVID-19 eradication might be slightly more feasible than for polio (although only two of three serotypes eradicated to date), but much less so than smallpox. ► The main challenges are probably around achieving high vaccination coverage and the potential need to update vaccine designs. Yet an advantage for COVID-19 eradication, over that for smallpox and polio, is that PHSMs can complement vaccination. There is also very high global interest in COVID-19 control due to the massive scale of the health, social and economic burden. ► There is a need for a more formal expert review of the feasibility and desirability of attempting COVID-19 eradication by the WHO or coalitions of national health agencies. Public and political concern about the health burden from the disease (including on health inequalities) ++ At the time the programme started in 1959: probably moderate concern in the 59 countries with endemic disease; total of ≥20 million cases/ year 32 + At the time the programme started in 1988: probably some concern in the 125 countries with endemic disease; total of 350 000 cases/year 32 +++ Very high in nearly all countries; an estimated 7.1 million deaths globally from January 2020 to 3 May 2021 33 To make comparisons between smallpox, polio, and COVID-19, we consider established technical factors that favour the eradicability of vaccine-preventable diseases, published in 1999 4 (table 1) . To this list we added additional technical, socio-political, and economic factors that are likely to favour achieving eradication. On our scoring for eradicability using a three-point relative scale across 17 variables, the mean (total) scores were smallpox at 2.7 (43/48), then COVID-19 at 1.6 (28/51), and finally polio at 1.5 (26/51) (table 1). While our analysis is a preliminary effort with various subjective components, it does seem to put COVID-19 eradicability into the realms of being possible, especially in terms of technical feasibility. The technical challenges of COVID-19 eradicability (relative to smallpox and polio) include poor vaccine acceptance, and the emergence of more variants that may be more transmissible or have greater immuno-evasion, potentially allowing vaccine escape so they can outrun global vaccination programmes. 11 Nevertheless, there are of course limits to viral evolution, so we can expect the virus to eventually reach peak fitness 12 and new vaccines can be formulated. Other challenges would be the high upfront costs (for vaccination and upgrading health systems), and achieving the necessary international cooperation in the face of 'vaccine nationalism' and government-mediated 'antiscience aggression'. 13 Another concern is the risk of the persistence of the pandemic virus in non-human animal reservoirs. However, wild animal infections with SARS-CoV-2 appear to be fairly rare to date, 14 and when companion animals become infected they do not appear to re-infect humans. 15 Infections among farmed animals could potentially be controlled by quarantining and culling. Furthermore, COVID-19 vaccines for domestic animals are being developed (as they were for the eradication of rinderpest 2 ) and oral vaccine in bait has effected successful regional elimination of rabies in wild foxes. 16 Furthermore, the problem of Guinea worm infection in domestic dogs has not stopped the global eradication efforts for that disease, 5 since various non-vaccination control measures can be successfully used in dogs. On the other hand, the massive scale of the health, social and economic burden from COVID-19 in most of the world means that there is unprecedented global interest in disease control and massive investment in vaccination against the pandemic. There is also the advantage for COVID-19 Public and political concern about the social and economic impacts of the disease (from illness and control measures required) + As per the row directly above; but also around the ongoing cost of vaccination in both endemic and non-endemic countries eradication over these other diseases in that PHSMs can be highly effective and can complement vaccination. The upgrading of health systems to facilitate COVID-19 eradication could also have large co-benefits for controlling other diseases (and indeed eradicating measles as well). Collectively these factors might mean that an 'expected value' analysis could ultimately estimate that the benefits outweigh the costs, even if eradication takes many years and has a significant risk of failure. The preliminary assessment we have performed indicates the value of further work on the potential for the eradication of COVID-19. This work would ideally be done by the WHO, but failing that it could be done by coalitions of national-level agencies working collaboratively. Any expert review needs to consider two main questions: (1) Could sustained COVID-19 eradication be technically feasible with currently available technologies? (2) Should eradication be attempted based on its desirability in terms of benefits versus costs (which provides the context of opportunity cost) and the risk of failure? It should also take a more sophisticated approach than we have by giving the different categories weights and also by making comparisons with measles, where elimination has been achieved at times for large regions (eg, the Americas 17 ) and which is potentially eradicable. 5 Modelling work that integrates both the health and economic aspects of COVID-19 control (as per recent work in Australia 18 ) should also inform the decision-making processes. In this very preliminary analysis, COVID-19 eradication seems slightly more feasible than for polio, but much less so than for smallpox. There is a need for a more formal expert review of the feasibility and desirability of attempting COVID-19 eradication by the WHO or other agencies. Twitter Matthew J Boyd @matt_adapt Contributors NW, ODM and MB are New Zealand based public health physicians/ epidemiologists. AK is an epidemiologist. MJ is a philosopher and catastrophic risks researcher. Content of this analysis was drawn from the experience of smallpox and polio eradication and on the epidemiology and control of COVID-19 to date. NW conceived the paper and wrote the initial draft. MJB and MB contributed to methodological issues. All authors contributed to revisions of the text. All authors approved the final version of the manuscript. Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Competing interests ODM reports membership in three boards/committees: the Specialist Council of the New Zealand Medical Association; the GAVI Independent Review Committee; and the Immunisation Advisory Committee (in New Zealand). Patient consent for publication Not required. Provenance and peer review Not commissioned; internally peer reviewed. Data availability statement All data relevant to the study are included in the article. The principles of disease elimination and eradication Rinderpest: the veterinary perspective on eradication Two out of three wild poliovirus strains eradicated. polio global eradication initiative Eradication of vaccine-preventable diseases Summary of the 31st meeting of the International Task Force for Disease Eradication It's official: China has eliminated malaria Five reasons why COVID herd immunity is probably impossible Use of genomics to track coronavirus disease outbreaks SARS-CoV-2 under an elimination strategy in Hong Kong Elimination could be the optimal response strategy for covid-19 and other emerging pandemic diseases SARS-CoV-2 variants and vaccines Has SARS-CoV-2 reached peak fitness Restoring vaccine diplomacy The search for animals harbouring coronavirus -and why it matters Study suggests it is common for PET dogs and cats to catch COVID-19 from their owners Rabies eradication in Belgium by fox vaccination using vaccinia-rabies recombinant virus Available: https:// www3. paho. org/ hq/ index. php? option= com_ content& view= article& id= 12526: measles-elimination-in-the-americas& Itemid= 40721& lang= en Assessment of a range of simulated COVID-19 policy responses for social restrictions and lockdowns associated with health-adjusted life years and costs in The principles of disease elimination and eradication Centers for Disease Control and Prevention. Smallpox: ring vaccination (page last reviewed World Health Organization A single-dose intranasal Chad vaccine protects upper and lower respiratory tracts against SARS-CoV-2 Immunity from smallpox vaccine persists for decades: a longitudinal study COVID-19 pandemic planning scenarios Smallpox and season: reanalysis of historical data Centers for Disease Control and Prevention, epidemiology and prevention of vaccine-preventable diseases. 13th Edn New mutations raise specter of 'immune escape Herd immunity and implications for SARS-CoV-2 control Global eradication of polio: the case for "finishing the job Insights from a systematic search for information on designs, costs, and effectiveness of poliovirus environmental surveillance systems Making waves: collaboration in the time of SARS-CoV-2 -rapid development of an international co-operation and wastewater surveillance database to support public health decision-making Comparing measles with previous eradication programs: enabling and constraining factors Institute for Health Metrics and Evaluation. Estimation of total mortality due to COVID-19 An update to the economic outlook: 2020 to 2030. United States Congressional Budget Office Economic considerations for the eradication endgame An updated economic analysis of the global polio eradication initiative Covid: more than 200 leaders urge G7 to help vaccinate world's poorest. Guardian Economic burden of seasonal influenza in the United States Smallpox: history of smallpox (page last reviewed Exclusive: UK cuts polio funding by 95%. Devex France24. WHO warns of June-July Covax doses shortfall